Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Sanofi Signs Agreement to Acquire Colombian Pharmaceutical Company, Genfar

By BiotechDaily International staff writers
Posted on 15 Oct 2012
The French pharmaceutical giant Sanofi (Paris, France signed of a definitive agreement to acquire Genfar SA (Bogota, Colombia).

With this deal signed on October 2, 2012, Sanofi will become a market leader in Colombia and expand its range of cost-effective pharmaceutical agents in Latin America, according to GlobalData (London, UK), an international market research firm. GlobalData believes the race by pharmaceutical companies to establish themselves in the CIVETS (Colombia, Indonesia, Vietnam, Egypt, Turkey, and South Africa) countries might just have begun. With companies such as Eli Lilly and Pfizer already responding to analysts’ calls for prudence about the potential of emerging markets by reducing their forecasts, the CIVETS countries, which are regarded as second-generation emerging markets and holding significant potential, seem to be the next big thing.

Sanofi’s acquisition is one that could generate significant dividends to the company in the future. In an incredibly competitive global pharmaceutical market, the one who moves first can take advantage, which can frequently be a key determinant of success or failure for players in specific geographic markets. As a result, Sanofi could potentially establish itself as a powerhouse with in Colombia and strengthen the barriers to entry for other pharmaceutical companies that may decide to later enter--meaning, according to GlobalData spokespersons, “get in, bolt the door, and lose the key.” Moreover, the company could utilize its entry into Colombia as a starting point for penetrating other CIVETS countries.

Moreover, Sanofi could potentially achieve comparative advantage over its competitors by moving most of its labor-intensive processes to Colombia, and subsequently other second-generation emerging markets. The cost of labor is expected to be significantly lower in these markets than in first-generation emerging markets including China, India, and Brazil. Therefore, by moving into fruitful economies outside of emerging markets, which are destined to become overcrowded at some time because of the swift movement of pharmaceutical companies into them, Sanofi would enjoy reduced costs and consequently, be able to compete on price if the need arises.

According to GlobablData, by acquiring Genfar, Sanofi is jumping into second-generation emerging markets. It will be interesting to see what the pharmaceutical giant will do next.

Related Links:

Sanofi
Genfar
GlobalData



comments powered by Disqus

Channels

Genomics/Proteomics

view channel

New Program Encourages Wide Distribution of Genomic Data

A new data sharing program allows genomics researchers and practitioners to analyze, visualize, and share raw sequence data for individual patients or across populations straight from a local browser. The sequencing revolution is providing the raw data required to identify the genetic variants underlying rare diseases... Read more

Drug Discovery

view channel
Image: The nano-cocoon drug delivery system is biocompatible, specifically targets cancer cells, can carry a large drug load, and releases the drugs very quickly once inside the cancer cell. Ligands on the surface of the \"cocoon\" trick cancer cells into consuming it. Enzymes (the “worms\" in this image) inside the cocoon are unleashed once inside the cell, destroying the cocoon and releasing anticancer drugs into the cell (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Novel Anticancer Drug Delivery System Utilizes DNA-Based Nanocapsules

A novel DNA-based drug delivery system minimizes damage to normal tissues by utilizing the acidic microenvironment inside cancer cells to trigger the directed release of the anticancer drug doxorubicin (DOX).... Read more

Lab Technologies

view channel

Experimental Physicists Find Clues into How Radiotherapy Kills Cancer Cells

A new discovery in experimental physics has implications for a better determination of the process in which radiotherapy destroys cancer cells. Dr. Jason Greenwood from Queen’s University Belfast (Ireland) Center for Plasma Physics collaborated with scientists from Italy and Spain on the work on electrons, and published... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.